Linkedin X-twitter Instagram

Redefining Regenerative Medicine

Scalable Cures for Chronic Conditions

Revolutionary Stem Cell Therapies

At Chiron Therapeutics, we're developing cutting-edge stem cell therapies powered by our proprietary Suspension-Induced Stem Cell Transition (SIST) technology. Our pipelines focus on transforming patient cells into targeted therapies for cartilage regeneration and wound healing.

Cartilage Regeneration Wound Healing
Generating human cartilage-producing cells (chondrocytes) from human skin fibroblasts confirmed by Alcian blue staining (top) and Immunostaining (bottom).

Restoring Mobility: Non-Invasive Cartilage Repair

The Challenge: Current treatments for Osteoarthritis are invasive, often requiring painful bone marrow harvesting or total joint replacement.

 

Our Solution: We generate functional chondrocytes from simple skin cells. No surgery, no rejection—just regeneration.

  • Validated Chondrogenesis (Top, Alcian Blue Staining)
  • High-Purity Cell Differentiation (Bottom, Immunostaining)
  • Scalable Manufacturing (100x Yield)
Contact Us Next Therapy
Using the SIST platform, we can derive spheroids from dermal fibroblasts (top) and keratinocytes (bottom) that express mesenchymal stem cell (MSC)- and keratinocyte stem cell (KSC)-like properties that are favorable for wound healing in a clinical setting.

Accelerating Recovery: Advanced Wound Care

The Challenge: Chronic ulcers and severe burns often fail to heal due to a lack of viable skin precursors.

Our Solution: SIST™ technology produces rapid, high-volume keratinocytes to close wounds faster and reduce scarring.

Contact Us Previous Therapy

Interested in Investment Opportunities?

Contact our team to learn more about our exosome-powered skincare and wound care solutions, or explore potential collaboration opportunities.

 
Contact Us Learn About Our Company

Behzad Yeganeh, Ph.D.

Founder & Chief Executive Officer

Dr. Behzad Yeganeh is the visionary Founder and CEO of Chiron Therapeutics, a seasoned biotech leader with over 15 years of experience translating complex biological discoveries into commercially viable assets. A two-time founder and serial entrepreneur, Dr. Yeganeh combines deep technical expertise in molecular biology with a proven track record of launching successful ventures anchored by proprietary intellectual property.

As the inventor of the revolutionary SIST technology, Dr. Yeganeh achieved a breakthrough high yield in generation of adult stem cell without genetic modification. This IP-licensed invention positions Chiron Therapeutics at the forefront of regenerative innovation, unlocking transformative therapeutic and cosmetic applications for adult stem cells.

Dr. Yeganeh’s leadership extends from bench to pre-clinical validation, including extensive experience in GMP manufacturing and regulatory strategy, notably with Health Canada. He has demonstrated a strong ability to secure non-dilutive funding and drive R&D strategies that bridge the gap between scientific innovation and market reality.

Linkedin